A genomic test that says what it knows, what it does not know, and how much evidence stands behind each thing it states.
Each one carries its grade of evidence in the corner. You can open any of them and see exactly how it is presented in the sample report.
Regional composition with an adjustable confidence level, and the migration routes of your maternal lineage — and of the paternal one, if the sample has a Y chromosome.
See the sectionWhen you are not a carrier but the condition is expressed: homozygous, compound heterozygous or dominant.
See the sectionRecessive diseases you could pass on without having them. Each one states how much of it the chip covers, because a negative result does not carry the same weight in all of them.
See the sectionGrouped by system: metabolic, cardiovascular, oncological, autoimmune, neurological and bone.
See the sectionHow you respond to specific medications, with a traffic-light indicator by drug and by gene. It is the section with the strongest clinical support: almost everything follows international CPIC guidelines, and where it does not, it says so.
See the sectionLactose, caffeine, alcohol, folate. Each one with its level of evidence stated, which is not the same for all of them.
See the sectionMuscle fibre type, response to training and recovery. It is among the areas with the most uneven evidence, and each card carries its level.
See the sectionSkin, sleep and longevity. These are among the areas with the least scientific support in the industry, and the section says so before showing a single result.
See the sectionCommunicating genetic risk, on its own, does not change anyone's behaviour — a systematic review using Cochrane methods shows as much. The value of a test like this lies not in reporting risks but in the concrete clinical decisions it enables. That is why every finding carries its level stated.
Hollands et al., BMJ 2016;352:i1102 — systematic review with meta-analysis.
There is a professional guideline stating what to do. It can change clinical management.
The association is firm, but what it adds to what clinical assessment already tells us is limited.
Replicated across several studies, with no evidence that knowing it improves an outcome.
Traits with no clinical implication. They are included out of interest, not usefulness.
The report opens showing only what can change clinical management. The rest is there, but behind a switch. A genetic test that presents bitter-taste perception with the same weight as a clopidogrel interaction is not being honest with whoever reads it.
RYR1, CYP2D6, Atrofia muscular espinal, Síndrome de X frágil, Mucopolisacaridosis tipo II (Hunter), Alfa-talasemia: the platform does not resolve them, and they appear anyway with the reason. A report that leaves out what it did not measure reads as if it had ruled it out.
There is a kit, but the analysis is not outsourced: the same laboratory processes and interprets it, and it also holds your testing history. The report stays in your account permanently.
Sample collection, processing, quality control and interpretation are all done by the same laboratory, in Recoleta, Buenos Aires. None of the four is outsourced.
Atlas is the personal genomic test from Laboratorio Aclimu (Buenos Aires, Argentina, since 1991): microarray genotyping on Illumina Infinium Global Screening Array v3 (GSA-24 v3.0), interpreted by the laboratory itself. ARS 159,000, results in 30 days.
You confirm your email with a code, leave your details and choose how many kits. Nothing is paid yet.
With Mercado Pago, right then. As soon as it clears, the code for each kit arrives by email.
Each person registers theirs in their own account: that is what ties the sample to a name. If you were given a kit and have no account, you open one with the code at /kit.
Saliva or a cheek swab. At our premises it takes five minutes, or you take the kit with you and bring the tube back whenever you can.
After 30 days it is published in your account, with the level of evidence for every finding. It does not expire, and it is reinterpreted as the evidence advances.
About 30 days pass between the sample and the report, and the report stays in your account permanently.
Genotyping is done once: your data is already read. What changes is the interpretation — every year new variants are described and others are reclassified — so your report is reinterpreted with whatever is known by then, without repeating the sample. If anything of yours changes, we let you know.
Book the test — ARS 159,000Four chapters with interactives: what a microarray is, how your sample is processed and how the result is read.
The complete report with fictional data, to see exactly what you will receive.
What you get, what you do not get, and the cases in which this test is not the right one.